Trinity EvidenceFirst™

Life sciences companies strive to make real-world evidence (RWE) a routine part of their decision-making process, but face challenges optimizing their use of real-world data (RWD).

Trinity’s EvidenceFirst offerings deliver meaningful RWE solutions by providing an experienced partner to work alongside life sciences leaders, with the context to flexibly implement built-for-purpose insights – and to draw on the appropriate data assets, from each company’s existing array of data resources to Trinity’s unique in-house data portfolio.

Trinity EvidenceFirst generates consistent, actionable real-world insights that ultimately allow life sciences organizations to answer critical questions, including:

• Who are the patients?
• Where do you find them?
• How are they treated?
• What are their outcomes?

With EvidenceFirst, life sciences companies can back commercial decision-making with real-world data (RWD) under circumstances and timeframes that previously were not realistic.

• Market and Therapy Area Landscape Assessment

  New Product Planning leaders often need to make quick business development decisions—inputs into those decisions, like sizing patient populations and defining the disease and market landscape, need to be available in weeks to be useful.

  Early commercial assessments often need to balance available resource with optimal analysis level, as teams may not own relevant data or have the budget for a custom analytical project.

  With EvidenceFirst, life sciences companies can back commercial decision-making with real-world data (RWD) under circumstances and timeframes that weren’t previously realistic.

  • Data-driven insights across a range of key business needs are delivered within 2 weeks.
  • EvidenceFirst’s flexibility allows the use of the most appropriate data assets for the specific needs of each client, including Trinity’s unique network of direct data access.

  Trinity EvidenceFirst generates actionable real-world insights to assess market and therapy area landscapes, allowing clients to:

  • Inform market opportunity/prioritization assessments
  • Drive forecast assumptions
  • Profile patient demographics and common comorbidities
  • Characterize treatment and treater landscapes
  • Understand disease burden and cost of care

  Sample Insights Available in 2 Weeks Include

  Market Sizing

  • Claims diagnosed prevalence
  • Year-over-year growth rate
  • Incidence rate
  • Key patient demographics

  Treatment Landscape

  • Overall treatment rate
  • Treatment rate – class | product
  • Mono vs. combo treatment
  • Treatment consumption metrics*

  Engaged Specialists

  • Engaged specialties
  • Treating specialties
  • Setting of care utilization
  • Top facilities

  Disease Burden

  • Common comorbidities
  • Top clinical outcomes
  • Total cost of care per patient
  • Distribution in cost of care
  • Average cost by care setting

  * Average scripts per patient, days on therapy (DOT), and daily average consumption (DACON)

• Evidence-Based Value Arguments

  For HEOR leaders focusing on evidence planning, evidence generation and scientific dissemination, RWE provides a solid foundation that allows them to address their key research questions around the patient, burden of illness and therapy/treatment landscape. The core challenge is two-fold:

  • Pre-launch — demonstrate and measure unmet needs in the current marketplace to pave the way for the upcoming launch
  • Peri-launch/On-Market Support — articulate the measurable value of your asset and differentiate it to ensure a successful market access and reimbursement strategy

  With EvidenceFirst, HEOR teams can generate robust publication-quality RWE to uncover unmet needs in the market, inform the launch strategy, drive Payer Communications and Medical Education and identify specific evidence to provide model inputs for Cost of Care models, Cost Effectiveness Analysis (CEAs) and Budget Impact Models (BIMs).

  • EvidenceFirst’s flexibility drives accuracy and confidence in identifying the right patients by using the most appropriate data assets and analytics for the specific needs of each question, including Trinity’s unique network of direct data access.
  • Trinity’s integrated approach allows clients to tap into dedicated, experienced HEOR and RWE teams for support across the product lifecycle.

  EvidenceFirst provides thoughtfully designed, customized RWE that allows clients to provide insights on key HEOR topics:

  • Epidemiology
  • Patient identification and characterization
  • Therapy use, LOT, switch behavior and discontinuation
  • Outcomes, SEs and AEs
  • Health Care Resource Utilization (HCRU) and Cost of Care
  • Unmet needs

  EvidenceFirst offers important, publication-quality insights to help:

  • Demonstrate product differentiation
  • Conduct appropriate statistical testing and comparator analyses — including matched cohort/baseline/reference
  • Identify compelling economic evidence to support payer engagement
  • Develop compelling clinical and humanistic evidence to support medical education

  Insights Include

  Patient & Provider Details

  • Epidemiology and demographics of physicians and patients
  • Setting of care
  • Patient cohorts of interest by disease state, LOT, etc.

  Current Treatment & Timeline

  • Test rates by physician and patient types
  • Time from diagnosis to treatment initiation
  • Unmet need (co-morbidities, diagnosis delay, etc.)
  • Treatments utilized (LOT) and source of business
  • Drivers of treatment utilization

  Treatment Experience

  • Duration and adherence to treatment by therapy type
  • Switching quantification
  • Patient experience
  • Drivers of treatment adherence

  Cost of Care

  • Healthcare cost, resource utilization and holistic cost of care
  • Cost distribution by setting of care and patient types
  • Drivers of cost

   

   

  Trinity’s Evidence Strategy Focus

  In today’s competitive markets, the challenge is not only to articulate and quantify the value of a product—but also to differentiate it from competitors and the existing standard of care, to support a strategic price point and to ensure a successful medical communication, market access and reimbursement strategy.

  Trinity’s Evidence Strategy team helps clients build and develop a compelling value story, demonstrate must-have evidence and drive scientific dissemination:

  • Critical Evidence Review & Gap Assessment
  • Evidence Generation Plan & RWE Roadmap
  • Medical Chart Audits, BoI & Patient Journey, HCP & Patient Choice / Preference
  • Systematic Literature Reviews
  • Predictive Analytics & HECON Modeling
  • KOL Mapping and Engagement
  • Publications Planning & Scientific Dissemination (Posters/Manuscripts)
  • PIE Deck / AMCP Dossier / GVDs / Objection Handler
  • And much more…
• Patient/Treatment Flow

  As Patient Centricity continues to rise in importance, pre-launch teams focusing on the Patient Journey can tap into the reach and objectivity of RWE-driven patient flows to support brand and launch planning.

  With EvidenceFirst, life sciences companies can follow patients over time to quantify the diagnostic and treatment journey.

  • EvidenceFirst’s flexibility allows the use of the most appropriate data assets for the specific needs of each client, including Trinity’s unique network of direct data access.
  • A proprietary analytics infrastructure allows clients to define custom patient cohorts, compare patient flows among subpopulations and understand multiple years of progression to understand gaps in care and better meet patient needs.

  EvidenceFirst identifies leverage points to optimize care, allowing clients to:

  • Determine opportunities within the market
  • Identify key levers, drivers and barriers in the market
  • Assess and prioritize stakeholders
  • Characterize the treatment and treater landscape

  Insights Include

  Treatment Journey

  • Treatment initiation timeline
  • Mono vs Combination use
  • Line of therapy progression
  • Switching and triggers for switch

  HCP Interaction

  • Specialty diagnosis and treatment
  • Specialty initiation
  • Referral flow
  • Specialty impact on treatment choice

  Diagnostic Flow

  • Events pre diagnosis
  • Tests conducted pre diagnosis*
  • Events post initial diagnosis
  • Time intervals between diagnosis and initiation of therapy

  Health Resource Utilization

  • Setting of care utilization
  • Site of care interaction as triggers for progression

  * Only lab tests that are coded. Results and ranges are not available.

   

  • Integrating RWE-based patient flows with PMR enables objective insights—such as diagnostic tests and frequency, referral pathways, triggers for therapy switching and more—to be coupled with the personal and professional perspectives of patients and HCPs. Clients gain insights to help guide project design, like point-in-time metrics, as well as to help contextualize and ground it.
  • Trinity’s dedicated Patient Centricity Center of Excellence focuses on deeply understanding patient needs and experiences to support life science organizations in product development, launch and beyond. Clients can select from a suite of patient-centric solutions, including: Patient Journey, Patient Experience Design, Patient Services Innovation and more.
• Brand Health Assessment

  For in-market brands, assessing brand performance and key levers that impact that performance—with market context—is crucial.

  Brands that haven’t yet entered a market need to compare themselves to competitors to inform strategy and planning.

  Trinity’s unique blend of assets and expertise allow clients to consider a range of brand health methodologies beyond standard analytics, including:

  • RWE “Data Assessments”—objective, data-driven views of a brand’s key performance levers and trends
  • Benchmarking—of historical spend and resourcing vs. competitors/peers/analogues
  • EvidenceFirst’s flexibility allows the use of the most appropriate data assets for the specific needs of each client, including Trinity’s unique network of direct data access

  Trinity EvidenceFirst generates actionable real-world insights to assess performance for brands or target markets relative to competitors, allowing clients to:

  • Identify levers for performance optimization
  • Define or update KPIs
  • Monitor market developments
  • Update and manage internal expectations

  Insights Include

  Physician Adoption

  • Percent of target specialists prescribing
  • Adoption over time
  • New vs. continuing prescribers

  Physician Prescribing

  • Brand- and target competitor-specific treatment rates
  • Differential prescribing rate by physician patient volume
  • Shared vs. owned prescribers
  • Use by indication

  Payer Acceptance

  • Relative adoption by payer channel
  • Performance with leading payers

  Patient Persistence

  • Days on therapy
  • 30/60/90-day patient drop-off rate
  • OOP sensitivity
• Patient Finding Excellence

  For leaders focusing on diseases in small patient populations, patient finding is vitally important across the product lifecycle:

  • Clinical teams need to identify patients that may not be diagnosed for trial recruitment and site selection
  • Commercial leaders need to scale the ability to find patients—diagnosed and undiagnosed—for planning, targeting and alerting.

  Patient finding is the foundation for market sizing and forecasting, the preface for commercial activities and planning—a core driver to understanding opportunity in a disease space.

  With EvidenceFirst, life sciences companies can leverage the rapidly evolving data ecosystem to enable strategy and execution driven by RWE across the product lifecycle. Patient Finding can be useful across a range of business needs—from critical clinical decisions, such as site selection, to commercial initiatives, like Next Best Action (NBA) and alerting.

  • EvidenceFirst’s flexibility drives accuracy and confidence in identifying the right patients by using the most appropriate data assets and analytics for the specific needs of each question, including Trinity’s unique network of direct data access.
  • Trinity’s integrated, patient-centric focus informs the process, allowing clients to find patients in time to address their critical needs.

  EvidenceFirst drives scalable, rapid patient finding to support commercial success, allowing clients to:

  • Engage physicians treating patients of interest
  • Accurately size the market and opportunity
  • Drive forecast assumptions
  • Characterize the treatment and treater landscape
  • Profile patient demographics and comorbidities
  • Evidence generation and value proposition

   

  Insights Include

  Market Sizing

  • Diagnosed and undiagnosed
  • Year-over-year growth rate
  • Incidence rate
  • Key patient demographics

  Engaged Stakeholders

  • Engaged specialists
  • Treating specialties
  • Setting of care utilization
  • Top facilities/site selection to target

  Treater Landscape

  • Overall treatment rate
  • Treatment rate by class | product
  • Mono vs. combination treatment
  • Treatment consumption metrics

  Disease Burden

  • Common comorbidities
  • Top clinical outcomes
  • Total cost of care per patient
  • Distribution in cost of care